Clinical Trials
2 trialsNCT02277392 2018-09-27
A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Withdrawn
NCT00659178 2017-07-21
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
GlaxoSmithKline
Phase 1 Completed